



**Request for Proposals (RFP)  
2023 HTRS/Novo Nordisk Clinical Scholar Award in  
Hemophilia and Rare Bleeding Disorders**

**Deadline: Wednesday, December 14, 2022 by 11:59 P.M. ET**  
via HTRS Online Grant Submission site: <https://htrs.smapply.org>

**HTRS/Novo Nordisk Clinical Scholar Award Program**

HTRS and Novo Nordisk Inc. (Novo) announce the availability of one Clinical Scholar Award (CSA) focused on Hemophilia and Rare Bleeding Disorders for one academic year – July 1, 2023 to June 30, 2024.

The 2023 CSA is supported by an educational grant to HTRS from Novo. During the clinical scholar year, the 2023 CSA recipient is mentored by an experienced MD, MD/PhD, or DO working in hemophilia and rare bleeding disorders at an established U.S.-based hemostasis treatment center (HTC), hospital, or university.

Applicants must present an education plan for the CSA year to obtain expertise in the clinical care of patients with hemophilia and rare bleeding disorders. It is strongly encouraged to include a scholarly activity as part of the CSA plan. A scholarly activity may include participation in the mentor's clinical research, helping to develop a clinical or educational program, a quality improvement project, or committing to specific additional educational activities/coursework intended to advance a career in hemostasis clinical care or research.

The goals of the Clinical Scholar Award Program are to:

1. Provide financial support for an early-career physician interested in enhancing his/her clinical training in hemostasis by engaging in a 12-month, intensive clinical scholar year focused on Hemophilia and Rare Bleeding Disorders under the guidance of an experienced mentor.
2. Combat the shortage of skilled non-malignant hematologists in the U.S. by providing funding, mentorship, and career development support to an early-career physician pursuing this career path.

The maximum grant is \$119,600 USD, including an \$80,000 stipend for the award recipient and a \$39,600 stipend for the primary mentor at the U.S.-based HTC, hospital or university identified in the applicant's proposal.

## Eligibility Requirements for Applicants

CSA applicants must meet the following eligibility criteria:

- Applicants must be U.S.-based MDs or DOs in pediatric or adult medicine
- Applicants must have completed the first two years of fellowship in an accredited U.S. Hematology, Hematology/Oncology, or Pediatric Hematology/Oncology training program. Applicants currently in training are encouraged to apply if they anticipate completing fellowship by July 1, 2023.
- Applicants up to five (5) years post-fellowship as of July 1, 2023 are eligible to apply. Individuals who have already achieved the rank of Associate Professor or who have held faculty positions for longer than five (5) years post-fellowship, are *not* eligible to apply.
- Applicants must identify a mentor who is an experienced academic physician or physician-scientist (MD, MD/PhD, or DO) working in Hemophilia and Rare Bleeding Disorders at a U.S.-based HTC, hospital, or university.
- Applicants may identify a co-mentor if training opportunities during the scholar year would be enhanced by the participation of a co-mentor. Either the applicant's primary mentor OR co-mentor is required to be an HTRS Core member prior to the CSA application submission deadline.
- Both the mentor, co-mentor (if applicable), and the recipient institution must agree to host and supervise the CSA award recipient by signing a legal Grant Agreement to be prepared by HTRS prior to the start of the CSA grant period.
- **HTRS Membership Requirements.** Applicants still in fellowship must activate their free HTRS Trainee Memberships prior to the CSA application deadline at [www.htrs.org](http://www.htrs.org). Junior Faculty hematologists who are not currently HTRS members, if chosen to receive a 2023 CSA, must sign up for HTRS Core Membership as a condition of their award acceptance prior to signing the formal Grant Agreement. For CSA recipients, either the mentor or co-mentor is encouraged to maintain HTRS Core membership for the duration of the grant period including during an approved no-cost extension.
- Previous HTRS Mentored Research Award or HTRS/ATHN DREAM Award recipients may apply for the CSA if the clinical scholar period does not overlap with either of these award periods. Previous HTRS/Novo Nordisk CSA recipients are ***not*** eligible to apply. Applicants generally may ***not*** ***receive*** more than one HTRS award with overlapping grant periods in a given year. Applicants applying in the same year for both the CSA and another HTRS award should contact HTRS at [jziegler@htrs.org](mailto:jziegler@htrs.org) to discuss eligibility before preparing a CSA application.

## Available Funding and Use of Funds

The 2023 CSA Program is supported by a medical educational grant to HTRS from Novo Nordisk Inc. The maximum CSA is \$119,600 USD, which includes an \$80,000 stipend to support the recipient's clinical training in Hemophilia and Rare Bleeding Disorders for one year, and a \$39,600 honoraria for

the applicant's primary mentor and/or co-mentor. CSA funds support only these expenses and cannot be used for any other direct or indirect costs associated with the scholar year without prior written permission from HTRS. If presenting a case for other direct or indirect costs, a budget must be provided within the narrative section of the application.

Funding of \$119,600 USD will be distributed by HTRS to the recipient institution in three payments:

- 1) The first payment of \$59,800 USD (50%) will be issued after full execution of the legal Grant Agreement contract between HTRS, the awardee, and the recipient institution.
- 2) The second payment of \$47,840 USD (40%) will be issued after acceptance by HTRS of a formal six-month *Progress Report* describing the awardee's progress toward achieving the goals and objectives outlined in the CSA application.
- 3) The third payment of \$11,960 USD (10%) is contingent upon acceptance by HTRS of a *Final Report* summarizing the completed 12-month scholarship period.

Instructions about required reports are communicated to the successful applicant in the CSA notification letter and Grant Agreement contract.

## Preparing a 2023 CSA Proposal

To apply for a 2023 CSA, applicants must submit a complete proposal to HTRS via our online grant submission site at <https://htrs.smapply.org> on or before **Wednesday, December 14, 2022 at 11:59 p.m. ET**. The system will confirm receipt via email. **If you submit an application but do not receive a confirmation email within 72 hours, please contact [jziegler@htrs.org](mailto:jziegler@htrs.org) for confirmation of receipt.** The site allows you to save your application to complete at a later date.

## Components of a Complete CSA Proposal

### 1. Application Form

Applicants are required to complete the Application Form in the HTRS online grant submission site.

### 2. Applicant Narrative (5 pages maximum, excluding references)

The CSA Narrative should be uploaded to the HTRS online grant submission site as a PDF. The elements of a complete CSA narrative include:

- a. A statement of commitment to a career in Hemophilia and Rare Bleeding Disorders, including future career plans
- b. A description of the applicant's background and preparation for a career in Hemophilia and Rare Bleeding Disorders
- c. Education plan to obtain expertise in the clinical care of patients with Hemophilia and Rare Bleeding Disorders. Applicants are strongly encouraged to include a scholarly activity in their goals that goes beyond the clinical care of patients (e.g. assisting in a mentor's clinical research, helping to develop a program, or committing to additional education meant to advance a career in hemostasis clinical care or research, such as quality improvement). Please include a statement recognizing the following minimum requirements for clinical time during the scholar year:
  - i. Longitudinal outpatient clinic experience with a focus on diagnosing and management patients with bleeding disorder for at least 1 half-day each week



grant period. Change in Status notification letters are subject to review and approval by HTRS. While most requests for Change in Status are negotiable, it should be noted that a change in career direction from an academic institution to commercial industry, for example, is not permitted per CSA eligibility requirements and will result in the award recipient returning the balance of the CSA funding to HTRS. Exact conditions and instructions for submitting a Change in Status request are outlined in the Grant Agreement contract.

3. Award Administration. The day-to-day administration of award funds is the responsibility of the recipient institution. As such, the recipient institution issues award funds as outlined in the approved project budget \$80,000 for the awardee's stipend and \$39,600 for the mentor's honoraria, as outlined above according to its own procedures and payment schedules. Funds are not sent to award recipients directly.

4. Articles, Abstracts, and Oral/Poster Presentations and Acknowledgements. Any articles (published and in progress), abstracts, or oral and poster presentations resulting from the CSA must acknowledge the support of both HTRS and Novo Nordisk Inc. as outlined in the applicant's award notification letter and the fully executed Grant Agreement contract. After the grant period, the awardee is required to provide HTRS with a final published copy of any articles, abstracts, or oral and poster presentations resulting from his/her scholar year that includes appropriate acknowledgement of award support.

5. Required Reports. The awardee is required to submit two formal reports via the HTRS grant system: 1) a Progress Report after the first six months of the clinical scholar period, and 2) a Final Report within three months of the completion of the award period. HTRS is required to share these reports with Novo. As such, the awardee should prepare his/her report to include supporter acknowledgment as outlined in his/her Grant Agreement contract. Required reports must also include a list of any articles (published and in progress), abstracts, or oral and poster presentations resulting from the CSA-funded scholar year, with copies of articles (published and in progress), abstracts, or oral and poster presentations appended. Awardees accept primary responsibility for understanding when reports are due and for following submission instructions provided by HTRS.

a. Progress Report: This report is a narrative of progress made during the first six months of the clinical scholar year. The report must be submitted via the HTRS grant system. The second payment of the Grant is contingent upon satisfactory progress having been made during the first six months, as determined by HTRS, per the goals and objectives outlined in the original CSA application. Unless other arrangements are made in advance, HTRS reserves the right to delay or withhold the second payment if: 1) the Progress Report is not submitted by the deadline listed in the Grant Agreement contract, or 2) evidence of satisfactory progress for the scholar year is not made available.

b. Final Report: This report consists of two parts: a narrative report of progress made over the entire award period and a financial report outlining expenses incurred during the entire award period. Both reports must be submitted via the HTRS online grant system. The third and final payment of the Grant is contingent upon: 1) satisfactory progress having been made during the tenure of the award as determined by HTRS, per the goals and objectives outlined in the original application; and 2) acceptance by HTRS of expenses submitted by the recipient institution, as compared to the most current, approved version of the clinical scholar budget. Unless other arrangements are made in advance, HTRS reserves the right to delay or withhold funds for the third and final payment if: 1) the Final Report is not submitted by the deadline listed in the Grant Agreement contract, or 2) evidence of satisfactory progress is not made available.

## **Application Review Process**

Proposals submitted by **Wednesday, December 14, 2022 at 11:59 p.m. ET** will be reviewed by members of the HTRS CSA Review Committee, a peer review committee of HTRS member physicians. Any reviewer with a direct conflict of interest (such as a close personal or professional relationship with any applicant) is recused from reviewing the specific application in question.

The Review Committee performs the best possible review based on data submitted by each applicant. The Committee's goal is to select the most competitive proposal for funding. HTRS regrets that due to the limited funding available, it is not possible to award scholar years to all applicants. Final funding approval is granted by the HTRS Board of Directors.

Applications will be judged according to the following criteria:

- a. The quality and potential of the applicant, including the demonstration of a sincere commitment to a career in Hemophilia and Rare Bleeding Disorders
- b. The quality of the proposed mentor/co-mentor and institution, as well as the demonstration of a sincere commitment by the mentor and institution to support the applicant
- c. The quality of the stated goals and objectives for the scholar year. Applicants are strongly encouraged to include a scholarly activity in their goals that goes beyond the clinical care of patients (e.g. assisting in a mentor's clinical research, helping to develop a program, or committing to additional education meant to advance a career in hemostasis clinical care or research, such as quality improvement).
- d. The relevance and potential impact of the scholar year to the applicant's stated career goals

## **Announcement of Award Recipients**

The announcement of the 2023 HTRS/Novo Nordisk CSA award recipient will be made no later than early March 2023 for the grant period beginning on July 1, 2023 and running through June 30, 2024. Award funds will be disbursed within 30 days of the date of execution of the legal Grant Agreement contract between HTRS and the recipient institution.

## **Past Recipients: Value of program**

To reflect the value of this experience, the following testimonials attest to the positive outcomes gained as reported by these past HTRS-member CSA recipients:

### ***Holleh D. Husseinzadeh, MD, MSCE 2016 Award Recipient (formerly named Clinical Fellowship)***

*"During my HTRS/Novo Nordisk Clinical Fellowship, I grew tremendously as a clinician and subspecialist within the non-malignant hematology specialty. I believe this experience is largely responsible for the attainment of my current position as Assistant Professor at Thomas Jefferson University Hospitals. I would like to wholeheartedly thank HTRS and Novo Nordisk for the honor of this fellowship."*

**Tiffany F. Lucas, MD, 2016 Award Recipient**

*\*Pediatric hematology/oncology fellowship program director at UCSF Benioff Children's Hospital San Francisco. In addition, received the Clinician Educator Award from American Society of Pediatric Hematology/Oncology and awarded by the American Society of Hematology for the Medical Educator's Initiative.*

**Beth Warren, MD, 2015 Award Recipient**

*"The HTRS CSA allowed me to have protected research time following my peds hem/onc fellowship – this award launched my clinical research career. While my fellowship research project had been in lab research, as time progressed I suspected that I would be a better match for clinical research, and this ended up being true! The HTRS CSA allowed me protected time to analyze a project previously started by my mentor. I was able to enroll in a master's of science of clinical science program at the same time, and use the statistics skills I was learning directly on the project, which really cemented those skills. The results led to exploring other possible modifiers of joint outcomes, which led to a K23 grant application that has recently been favorably scored. The mentorship was completely critical. I would have floundered more if not for my mentor, who helped me realize that research and patient care are very intertwined, and that I didn't have to choose between them.*

*\*Assistant Professor, University of Colorado Anschutz Medical Campus*

**Disclosure of HTRS Compliance with State or Federal Requirements per *Open Payments: The Physician Payments Sunshine Act***

The HTRS/Novo Nordisk Clinical Scholar Award may be reportable by law to state or federal agencies under *Open Payments: The Physician Payments Sunshine Act* ("Sunshine Act"). HTRS may be required to share information about the CSA recipient institution, awardee, mentor or co-mentor, or other particulars of this program with Novo Nordisk Inc.

Applicants to HTRS CSA Program are required to confirm, prior to submitting a proposal to HTRS, that their institution is able to accept grant funding that may be subject to Sunshine Act reporting. Applicants who have questions about the Sunshine Act should ask their institutional Office of Research or other grant administrator for more detail, since regulations can differ by institution and state.

**About HTRS**

The Hemostasis and Thrombosis Research Society, Inc. (HTRS) is the leading North American professional society dedicated to research, mentoring, workforce development, and continuing medical education for physicians, investigators, and all health care professionals interested in advancing care for people with hemostatic and thrombotic disorders.

**Questions**

Questions about the 2023 HTRS/Novo Nordisk Clinical Scholar Award in Hemophilia and Rare Bleeding Disorders should be directed to HTRS at [jziegler@htrs.org](mailto:jziegler@htrs.org).

*HTRS is grateful for educational grant support from **Novo Nordisk Inc.** for this clinical scholar program.*